Dementia Market Expected to Experience Major Growth by 2032, According to DelveInsight | Charsire Biotech Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP

The Key Dementia Companies in the market include - Charsire Biotechnology Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP Pharma, Johnson & Johnson, Materia Medica Holding, Eisai Co., Ltd., Shineway Pharma, Merz Pharma, Ever Neuro Pharma GmbH, Zhejiang Otsuka Pharma, Janssen, LP, GE Healthcare, and others.

DelveInsight's "Dementia Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Dementia, historical and forecasted epidemiology as well as the Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dementia Market Forecast [https://www.delveinsight.com/sample-request/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Dementia Market Report:

*
The Dementia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In October 2024, A Phase II clinical trial assessing Sinaptica Therapeutics' neuromodulation device for Alzheimer's disease successfully met its primary and key secondary endpoints. The SinaptiStim system delivers personalized brain stimulation through painless 20-minute weekly sessions, targeting the "precuneus," a vital region of the brain's default mode network (DMN) associated with memory and introspection. By stimulating this area, the therapy aims to enhance brain plasticity, strengthen memory pathways, and support cognitive function.

*
In October 2024, Alzamend Neuro, Inc. (Nasdaq: ALZN), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder, has announced the receipt of the complete data set from its multiple ascending dose clinical trial evaluating AL001 for dementia associated with Alzheimer's disease

*
In September 2024, Vesper Bio shared results from a Phase I trial of VES001, a potential disease-modifying therapy for frontotemporal dementia (FTD) aimed specifically at patients with progranulin gene mutations (GRN). The company administered the first dose to a participant in the trial last December. The study, which included 78 healthy volunteers, was conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic target engagement of VES001.

*
Over 55 million people worldwide are living with dementia, with numbers expected to triple by 2050 due to aging populations.

*
Nearly 10 million new cases of dementia are diagnosed each year.

*
Age-Related Risk - Dementia primarily affects older adults, with prevalence increasing significantly after 65 years of age.

*
Alzheimer's disease is the most common type of dementia, accounting for 60-80% of cases.

*
Women are at a higher risk than men, likely due to longer life expectancy and hormonal factors.

*
High-income countries have higher reported prevalence, but cases are rising rapidly in low- and middle-income countries (LMICs) due to aging populations and limited healthcare access.

*
Family history, cardiovascular diseases, diabetes, and unhealthy lifestyles (smoking, poor diet, lack of exercise) contribute to dementia risk.

*
Dementia-related costs are projected to exceed $1.3 trillion annually, placing a heavy burden on healthcare systems and caregivers.

*
Mortality Rate - Dementia is a leading cause of death, ranking among the top five causes of mortality in many developed nations.

*
Though rare, dementia can occur before 65 years of age, accounting for about 5-10% of all cases.

*
Key Dementia Companies: Charsire Biotechnology Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP Pharma, Johnson & Johnson, Materia Medica Holding, Eisai Co., Ltd., Shineway Pharma, Merz Pharma, Ever Neuro Pharma GmbH, Zhejiang Otsuka Pharma, Janssen, LP, GE Healthcare, and others

*
Key Dementia Therapies: BAC, PNA1, Apabetalone, CY6463, Butylphthalide soft capsule, galantamine, Prospecta, donepezil hydrochloride (Aricept), SaiLuoTong capsule, Akatinol Memantine, Cerebrolysin, Cilostazol, risperidone, DatSCAN, and others

*
The Dementia epidemiology based on age-specific cases analyzed that Dementia (VaD) is highly prevalent in age group of 60 years and above, while below this age group the disease appears to be rare

*
The Dementia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dementia pipeline products will significantly revolutionize the Dementia market dynamics.

Dementia Overview

Dementia is a progressive neurological disorder that affects memory, thinking, behavior, and the ability to perform daily activities. It is caused by damage to brain cells, leading to cognitive decline. Common types include Alzheimer's disease, vascular dementia, Lewy body dementia, and frontotemporal dementia. Symptoms include memory loss, confusion, difficulty in communication, and impaired reasoning. While there is no cure, treatments like medications, cognitive therapies, and lifestyle modifications can help manage symptoms and improve quality of life.

Get a Free sample for the Dementia Market Report:

https://www.delveinsight.com/report-store/dementia-market [https://www.delveinsight.com/report-store/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dementia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dementia Epidemiology Segmentation:

The Dementia market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Dementia

*
Prevalent Cases of Dementia by severity

*
Gender-specific Prevalence of Dementia

*
Diagnosed Cases of Episodic and Chronic Dementia

Download the report to understand which factors are driving Dementia epidemiology trends @ Dementia Epidemiology Forecast [https://www.delveinsight.com/sample-request/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dementia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dementia market or expected to get launched during the study period. The analysis covers Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dementia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dementia Therapies and Key Companies

*
BAC: Charsire Biotechnology Corp

*
PNA1: ProNeurogen Therapeutics

*
Apabetalone: Resverlogix

*
CY6463: Cyclerion Therapeutics

*
Butylphthalide soft capsule: CSPC-NBP Pharma

*
galantamine: Johnson & Johnson

*
Prospecta: Materia Medica Holding

*
donepezil hydrochloride (Aricept): Eisai Co., Ltd.

*
SaiLuoTong capsule: Shineway Pharma

*
Akatinol Memantine: Merz Pharma

*
Cerebrolysin: Ever Neuro Pharma GmbH

*
Cilostazol: Zhejiang Otsuka Pharma

*
risperidone: Janssen, LP

*
DatSCAN: GE Healthcare

Discover more about therapies set to grab major Dementia market share @ Dementia Treatment Market [https://www.delveinsight.com/sample-request/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Dementia Market Strengths

*
The increasing prevalent population in the 7MM is likely to cause an upsurge in treatment need. Consequently, with successful launch of emerging therapies, the market will witness a boost in the upcoming year.

Dementia Market opportunities

*
Medications with better safety and effectiveness, which provide optimum care are the current unmet need of the VaD disease market.

Scope of the Dementia Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Dementia Companies: Charsire Biotechnology Corp, ProNeurogen Therapeutics, Resverlogix, Cyclerion Therapeutics, CSPC-NBP Pharma, Johnson & Johnson, Materia Medica Holding, Eisai Co., Ltd., Shineway Pharma, Merz Pharma, Ever Neuro Pharma GmbH, Zhejiang Otsuka Pharma, Janssen, LP, GE Healthcare, and others

*
Key Dementia Therapies: BAC, PNA1, Apabetalone, CY6463, Butylphthalide soft capsule, galantamine, Prospecta, donepezil hydrochloride (Aricept), SaiLuoTong capsule, Akatinol Memantine, Cerebrolysin, Cilostazol, risperidone, DatSCAN, and others

*
Dementia Therapeutic Assessment: Dementia current marketed and Dementia emerging therapies

*
Dementia Market Dynamics: Dementia market drivers and Dementia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Dementia Unmet Needs, KOL's views, Analyst's views, Dementia Market Access and Reimbursement

To know more about Dementia companies working in the treatment market, visit @ Dementia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/dementia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Dementia Market Report Introduction

2. Executive Summary for Dementia

3. SWOT analysis of Dementia

4. Dementia Patient Share (%) Overview at a Glance

5. Dementia Market Overview at a Glance

6. Dementia Disease Background and Overview

7. Dementia Epidemiology and Patient Population

8. Country-Specific Patient Population of Dementia

9. Dementia Current Treatment and Medical Practices

10. Dementia Unmet Needs

11. Dementia Emerging Therapies

12. Dementia Market Outlook

13. Country-Wise Dementia Market Analysis (2019-2032)

14. Dementia Market Access and Reimbursement of Therapies

15. Dementia Market Drivers

16. Dementia Market Barriers

17. Dementia Appendix

18. Dementia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=dementia-market-expected-to-experience-major-growth-by-2032-according-to-delveinsight-charsire-biotech-corp-proneurogen-therapeutics-resverlogix-cyclerion-therapeutics-cspcnbp]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.